Tenax Therapeutics, Inc.

NasdaqCM TENX

Tenax Therapeutics, Inc. Price to Sales Ratio (P/S) on January 14, 2025: 3,785.72

Tenax Therapeutics, Inc. Price to Sales Ratio (P/S) is 3,785.72 on January 14, 2025, a 3,769.11% change year over year. Price to sales ratio compares the stock price to the sales per share; higher suggests positive sentiment for future revenue growth.

Tenax Therapeutics, Inc. 52-week high Price to Sales Ratio (P/S) is 3,898.48 on January 02, 2025, which is 2.98% above the current Price to Sales Ratio (P/S).
Tenax Therapeutics, Inc. 52-week low Price to Sales Ratio (P/S) is 28.88 on April 26, 2024, which is -99.24% below the current Price to Sales Ratio (P/S).
Tenax Therapeutics, Inc. average Price to Sales Ratio (P/S) for the last 52 weeks is 670.21.

Key data

Date	Price to Sales Ratio (P/S)	Price to Book Ratio (P/B)	Dividend Yield	Free Cash Flow Yield

NasdaqCM: TENX

Tenax Therapeutics, Inc.

CEO	Mr. Christopher T. Giordano
IPO Date	April 4, 1994
Location	United States
Headquarters	ONE Copley Parkway
Employees	5
Sector	Health Care
Industries Pharmaceuticals

Description

Tenax Therapeutics, Inc., a specialty pharmaceutical company, engages in identifying, developing, and commercializing products for cardiovascular and pulmonary diseases in the United States and Canada. It develops TNX-103 and TNX-102 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension associated with heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of pulmonary arterial hypertension. The company was formerly known as Oxygen Biotherapeutics, Inc. and changed its name to Tenax Therapeutics, Inc. in September 2014. Tenax Therapeutics, Inc. was founded in 1967 and is headquartered in Morrisville, North Carolina.

Key trends

Past 5 years